This essay was written by her colleagues, Jeanine Gordon and Jaclyn Andronico, Memorial Sloan Kettering Cancer Center, nominating Lisa Klempner, M.S.N., RN, OCN for CURE®’s 2019 Extraordinary Healer® Award.
It can be challenging and confusing to get prescription drugs paid for in Canada. Drug access navigators can help.
It's been 17 years since my diagnosis of stage 3a non–small cell lung cancer. I can remember that moment as if it was yesterday.
An Extraordinary Healer essay honoring Debbie O’Sullivan, RN, OCN [UT Health Northeast Cancer Treatment and Prevention Center in Tyler, Texas]
Chemotherapy and PARP inhibitors may share some side effects, but there are some major differences between the two when it comes to treating ovarian cancer.
A prostate cancer survivor offers his thoughts on what you should (and shouldn't) say to someone who was recently diagnosed.
An essay honoring SARA SARGENTE, RN, OCN [ORANGE REGIONAL MEDICAL CENTER, MIDDLETOWN, NEW YORK]
"I don’t have cancer, but here I am. This is my life. This is my reality. I am BRCA positive."
Long-term data from the phase 3 EF-14 study showed that Optune plus temozolomide had a survival benefit compared to temozolomide alone.
I didn’t like thinking of myself as a “survivor.” There was something … I don’t know. Something a little shameful, maybe, about it.
Navigating the emotional and practical hurdles of caring for parents and stepparents.
An Extraordinary Healer essay honoring Sharon Bird, BSN, RN [ THOMAS JEFFERSON UNIVERSITY HOSPITAL IN RADNOR, PENNSYLVANIA ]
Genetic testing – particularly for microsatellite instability (MSI) – is an important step for all patients diagnosed with colorectal cancer.
As the treatment paradigm shifts for triple-negative breast cancer, PARP inhibitors will continue to play a role.
Going in for an infusion amid the coronavirus pandemic with a possible "symptom" of COVID-19 and wondering what risks lie ahead.
Cannon McMullin was diagnosed with essential thrombocythemia at 8 years old and has remained positive through years of treatment by focusing on the things he likes to do.
Kay Verble discusses a research endeavor to characterize long-term survivors of glioblastoma multiforme (GBM).